Lennox sees mixed result from ‘buy now, pay later’ providers
The ‘buy now pay later’ market has delivered mixed results for the Lennox Capital Partners’ managers with ZipCo boosting performance while micro-cap firm Sezzle was a detractor.
ZipCo was held in the firm’s $187 million Australian Small Companies fund and was the top contributor to performance during September after it was added to the ASX Small Ordinaires index during the month.
In a monthly update, managers James Dougherty and Liam Donohue said: “Shares in ZipCo rose 29.5% during the month as it was added to the ASX Small Ordinaries index at the September rebalance. The company also acquired Spotcap for $8.825m, expanding its offering to the small and medium enterprise (SME) space. We also note it was a strong month for all buy now pay later companies with Afterpay up 49.0% and Flexigroup up 40.4%.”
However, this was not the case on the firm’s $12 million Australian Microcap fund where buy now pay later provider Sezzle was the largest detractor with falls in its share price of 5.6% during the month.
Lennox said it believed this was the result of investors taking profits following the company’s IPO at the end of July.
The Australian Small Companies fund has returned 9.3% over one year to 30 September, according to FE Analytics, while the Australian Microcap fund has returned 9.7% over the same period. This compared to returns of 5.5% by the ACS Equity- Australia Small/Mid Cap sector.
Performance of Lennox Australian Microcap and Australian Small Companies funds over one year to 30 September, versus ACS Equity- Australia Small/Mid Cap sector.
AUTHOR
Laura Dew
Recommended for you
Global X has painted a worrying picture for active ETFs in Australia, with investor adoption proving uneven and the popularity of its low-cost index counterparts only growing stronger.
Australian equity ETFs attracted record inflows of $3.2 billion in 1Q25, while heightened volatility led to a decline in flows for global equity ETFs, according to Vanguard.
The failure of a clinical trial by biotech firm Opthea has caused shares in its backer Regal Partners to decline 52 per cent year-to-date and hit its funds under management, quarterly flows show.
GQG Partners has revealed its quarterly flows for the first three months of 2025 were up 5.8 per cent, after a difficult final quarter of 2024 as a result of institutional redemptions.
